Brokerages Set Savara Inc. (NASDAQ:SVRA) PT at $10.14

Savara Inc. (NASDAQ:SVRA) has received a consensus rating of “Moderate Buy” from the eight analysts that are presently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, six have given a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $10.1429.

Several brokerages recently issued reports on SVRA. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Savara in a report on Friday, July 17th. Oppenheimer began coverage on shares of Savara in a research note on Friday, April 24th. They set an “outperform” rating and a $11.00 target price on the stock. Finally, Wall Street Zen upgraded Savara from a “sell” rating to a “hold” rating in a research note on Saturday, June 13th.

Hedge Funds Weigh In On Savara

Large investors have recently bought and sold shares of the company. Rhumbline Advisers grew its holdings in shares of Savara by 10.8% during the second quarter. Rhumbline Advisers now owns 170,176 shares of the company’s stock worth $388,000 after purchasing an additional 16,634 shares during the last quarter. Prudential Financial Inc. acquired a new position in shares of Savara in the second quarter valued at approximately $30,000. XTX Topco Ltd bought a new position in Savara in the 2nd quarter valued at approximately $201,000. Invesco Ltd. raised its holdings in Savara by 35.4% in the 2nd quarter. Invesco Ltd. now owns 120,891 shares of the company’s stock valued at $276,000 after buying an additional 31,633 shares during the last quarter. Finally, The Manufacturers Life Insurance Company boosted its position in Savara by 14.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 51,930 shares of the company’s stock worth $118,000 after buying an additional 6,449 shares during the period. 87.93% of the stock is currently owned by institutional investors.

Savara Price Performance

Shares of SVRA stock opened at $5.33 on Thursday. The business has a fifty day simple moving average of $5.58 and a 200 day simple moving average of $5.51. The company has a market cap of $1.09 billion, a P/E ratio of -9.52 and a beta of 0.29. The company has a quick ratio of 13.47, a current ratio of 13.47 and a debt-to-equity ratio of 0.17. Savara has a twelve month low of $2.43 and a twelve month high of $7.01.

Savara (NASDAQ:SVRA) last released its earnings results on Tuesday, May 12th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.01). On average, sell-side analysts forecast that Savara will post -0.57 EPS for the current fiscal year.

Savara Company Profile

Savara Inc (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.